Search the Newsreel

MacroGenics Inc (MGNX) Institutional Confidence

MacroGenics Inc (MGNX) currently holds an institutional shareholding score of 5.00, placing it 132nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 68.70%, marking a 14.58% increase quarter-over-quarter. James Simons is the largest institutional shareholder.

MacroGenics slips on trial data for lead asset (MGNX:NASDAQ)

MacroGenics (MGNX) shares fell by nearly 6% following the release of updated results from an ongoing Phase 1 trial for its lead asset, MGC026. The drug, an antibody-based therapy, is being developed to target solid tumors. The trial data involved 74 patients.

Enel Chile SA (ENIC) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Enel Chile SA's (ENIC) financial health, ranking it 4th out of 63 in the Electric Utilities & IPPs industry with a score of 8.63. It highlights the company's robust financial status and average operating efficiency, noting a year-over-year …

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

MacroGenics, Inc. announced a clinical update on its ongoing Phase 1 study for MGC026, a B7-H3-directed antibody-drug conjugate (ADC), for advanced solid tumors. Interim results, showing the achievement of a pre-specified response threshold in squamous cell carcinoma of the head and neck, will be …

MGNX stock holds focus as MacroGenics plans and pipeline metrics matter

MacroGenics (MGNX) is a small-cap biotech company whose stock performance is heavily influenced by pipeline execution, balance sheet health, and financial metrics like revenue and cash use. Investors should focus on the company's reported numbers, program milestones, and clinical data readouts rather than broad …

Enel Chile stock holds firm as earnings and dividend profile anchor valuation

Enel Chile's stock remains stable due to its consistent earnings, regulated cash flows, and attractive dividend yield, appealing to income-oriented investors. The company showcases a balanced financial profile with manageable leverage, substantial capital expenditures for network upgrades and renewables, and strong cash flow generation …

MacroGenics’ MGC026 meets trial threshold in head and neck cancer

MacroGenics Inc. announced that its Phase 1 study for MGC026, an antibody-drug conjugate, met the pre-specified response threshold in the head and neck cancer cohort, allowing it to advance to Stage 2 enrollment. Interim results from the study, which has enrolled 74 patients, will …

Argenica Therapeutics (ASX:AGN) Falls — What Comes Next for This ASX Biotechnology Stock?

ETFs Investing in Enel Chile SA Stocks

This article lists various ETFs that hold shares of Enel Chile SA (ENELCHILE0), detailing their market value, weight of Enel Chile SA in the fund, issuer, management style, focus, expense ratio, AUM, price, and 3-year total return. It provides a comprehensive overview for investors …

Enel Chile SA Revenue Breakdown – BCS:ENELCHILE0

Enel Chile SA's revenue for the last year reached ‪4.36 billion USD, with the Generation segment being the top performer, contributing ‪2.98 billion USD. Geographically, Chile was the largest contributor to revenue, accounting for ‪4.90 billion USD.

MacroGenics (MGNX): Millennium group discloses 3.7% beneficial stake in amended 13G

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended Schedule 13G for MacroGenics (MGNX), disclosing a collective beneficial ownership of 2,374,296 shares, which represents 3.7% of the outstanding common stock. This filing indicates that the reporting persons now …

US29278DAA3 Bond Profile — Key Metrics

This article provides key metrics for the Enel Chile S.A. 4.875% bond maturing on June 12, 2028, with the symbol US29278DAA3. It details the issuer's business, outlining its operations in electricity generation and distribution within Chile. Key financial facts such as issue date, maturity, …

MacroGenics stock gains after FDA priority review as revenue rises and cash runway extends

MacroGenics stock experienced gains following an FDA priority review for vobramitamab duocarmazine and significant revenue increases. The company reported a 31.1% rise in Q1 2024 revenue, totaling $45.7 million, with collaborative and licensing arrangements being the primary driver. This financial performance, coupled with reduced …

US29278DAA3 Bond Risk Profile

This page provides a risk profile for the Enel Chile S.A. 4.875% 12-JUN-2028 bond, identified by US29278DAA3, traded on the Dusseldorf Stock Exchange. It offers an overview of the bond, focusing on coupon, redemption, and various risks, along with key metrics for credit risk …

Enel Chile (SNSE:ENELCHILE) Stock Sees Modest Fair Value Lift After Neutral Analyst Calls

Enel Chile's fair value price target has seen a modest increase from CLP 82.43 to CLP 85.14, despite several analysts issuing more neutral recommendations. This adjustment comes against a backdrop of mixed views, with some firms like Itau BBA and BTG Pactual downgrading the …

US29278DAA3 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the Enel Chile S.A. 4.875% bond maturing on June 12, 2028, identified by US29278DAA3. It details the current coupon rate of 4.88% and notes that the next payment is scheduled for December 14, 2026. The page offers …

Price to sales forward of Anagenics Limited – ASX:AN1

Why You Might Be Interested In Elvalhalcor Hellenic Copper and Aluminium Industry S.A. (ATH:ELHA) For Its Upcoming Dividend

Irenic Acquisition (IACQ) Stock Price, News & Analysis

Irenic Acquisition to Separate Trading of Class A Shares and Warrants, IACQ/IACQW

ELIN: Revenue and profits grew year-over-year, with strong cash flow and full IPO proceeds utilization

DSM-Firmenich rapporteert sterke resultaten eerste kwartaal, overtreft verwachtingen

DSM-Firmenich FY 2025 presentatie: Aandeel stort 43% in ondanks solide resultaten

Earnings Not Telling The Story For Elin Electronics Limited (NSE:ELIN) After Shares Rise 25%

ELINOIL HELLENIC PETROLEUM COMPANY S.A. Dividends – ATHEX:ELIN

DSM-FIRMENICH AG (DSFIR.NV): aandelenkoers, nieuws en analistenvoorspellingen

Koers DSM FIRMENICH AG | Advies, nieuws, dividend en koersdoelen

Technical Analysis of ELVALHALCOR Hellenic Copper and Aluminium Industry S.A. (ATHEX:ELHA)

Anagenics Limited (ASX:AN1) - Shares, Dividends & News

ELINOIL HELLENIC PETROLEUM COMPANY S.A.